Altered expression and localization of tumor suppressive e3 ubiquitin ligase smurf2 in human prostate and breast cancer

Andrea Emanuelli, Dhanoop Manikoth Ayyathan, Praveen Koganti, Pooja Anil Shah, Liat Apel-Sarid, Biagio Paolini, Rajesh Detroja, Milana Frenkel-Morgenstern, Michael Blank

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

SMURF2, an E3 ubiquitin ligase and suggested tumor suppressor, operates in normal cells to prevent genomic instability and carcinogenesis. However, the mechanisms underlying SMURF2 inactivation in human malignancies remain elusive, as SMURF2 is rarely found mutated or deleted in cancers. We hypothesized that SMURF2 might have a distinct molecular biodistribution in cancer versus normal cells and tissues. The expression and localization of SMURF2 were analyzed in 666 human normal and cancer tissues, with primary focus on prostate and breast tumors. These investigations were accompanied by SMURF2 gene expression analyses, subcellular fractionation and biochemical studies, including SMURF2’s interactome analysis. We found that while in normal cells and tissues SMURF2 has a predominantly nuclear localization, in prostate and aggressive breast carcinomas SMURF2 shows a significantly increased cytoplasmic sequestration, associated with the disease progression. Mechanistic studies showed that the nuclear export machinery was not involved in cytoplasmic accumulation of SMURF2, while uncovered that its stability is markedly increased in the cytoplasmic compartment. Subsequent interactome analyses pointed to 14-3-3s as SMURF2 interactors, which could potentially affect its localization. These findings link the distorted expression of SMURF2 to human carcinogenesis and suggest the alterations in SMURF2 localization as a potential mechanism obliterating its tumor suppressor activities.

Original languageEnglish
Article number556
JournalCancers
Volume11
Issue number4
DOIs
Publication statusPublished - Apr 2019

Fingerprint

Ubiquitin-Protein Ligases
Prostatic Neoplasms
Breast Neoplasms
Neoplasms
Prostate
Carcinogenesis
Cell Nucleus Active Transport
Genomic Instability
Disease Progression
Gene Expression

Keywords

  • Gene and protein expression
  • Interactome
  • Molecular localization
  • Prostate and breast cancer
  • SMURF2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Altered expression and localization of tumor suppressive e3 ubiquitin ligase smurf2 in human prostate and breast cancer. / Emanuelli, Andrea; Ayyathan, Dhanoop Manikoth; Koganti, Praveen; Shah, Pooja Anil; Apel-Sarid, Liat; Paolini, Biagio; Detroja, Rajesh; Frenkel-Morgenstern, Milana; Blank, Michael.

In: Cancers, Vol. 11, No. 4, 556, 04.2019.

Research output: Contribution to journalArticle

Emanuelli, A, Ayyathan, DM, Koganti, P, Shah, PA, Apel-Sarid, L, Paolini, B, Detroja, R, Frenkel-Morgenstern, M & Blank, M 2019, 'Altered expression and localization of tumor suppressive e3 ubiquitin ligase smurf2 in human prostate and breast cancer', Cancers, vol. 11, no. 4, 556. https://doi.org/10.3390/cancers11040556
Emanuelli, Andrea ; Ayyathan, Dhanoop Manikoth ; Koganti, Praveen ; Shah, Pooja Anil ; Apel-Sarid, Liat ; Paolini, Biagio ; Detroja, Rajesh ; Frenkel-Morgenstern, Milana ; Blank, Michael. / Altered expression and localization of tumor suppressive e3 ubiquitin ligase smurf2 in human prostate and breast cancer. In: Cancers. 2019 ; Vol. 11, No. 4.
@article{24eca2c19d5c4c6ea557b63e03d54cab,
title = "Altered expression and localization of tumor suppressive e3 ubiquitin ligase smurf2 in human prostate and breast cancer",
abstract = "SMURF2, an E3 ubiquitin ligase and suggested tumor suppressor, operates in normal cells to prevent genomic instability and carcinogenesis. However, the mechanisms underlying SMURF2 inactivation in human malignancies remain elusive, as SMURF2 is rarely found mutated or deleted in cancers. We hypothesized that SMURF2 might have a distinct molecular biodistribution in cancer versus normal cells and tissues. The expression and localization of SMURF2 were analyzed in 666 human normal and cancer tissues, with primary focus on prostate and breast tumors. These investigations were accompanied by SMURF2 gene expression analyses, subcellular fractionation and biochemical studies, including SMURF2’s interactome analysis. We found that while in normal cells and tissues SMURF2 has a predominantly nuclear localization, in prostate and aggressive breast carcinomas SMURF2 shows a significantly increased cytoplasmic sequestration, associated with the disease progression. Mechanistic studies showed that the nuclear export machinery was not involved in cytoplasmic accumulation of SMURF2, while uncovered that its stability is markedly increased in the cytoplasmic compartment. Subsequent interactome analyses pointed to 14-3-3s as SMURF2 interactors, which could potentially affect its localization. These findings link the distorted expression of SMURF2 to human carcinogenesis and suggest the alterations in SMURF2 localization as a potential mechanism obliterating its tumor suppressor activities.",
keywords = "Gene and protein expression, Interactome, Molecular localization, Prostate and breast cancer, SMURF2",
author = "Andrea Emanuelli and Ayyathan, {Dhanoop Manikoth} and Praveen Koganti and Shah, {Pooja Anil} and Liat Apel-Sarid and Biagio Paolini and Rajesh Detroja and Milana Frenkel-Morgenstern and Michael Blank",
year = "2019",
month = "4",
doi = "10.3390/cancers11040556",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - Altered expression and localization of tumor suppressive e3 ubiquitin ligase smurf2 in human prostate and breast cancer

AU - Emanuelli, Andrea

AU - Ayyathan, Dhanoop Manikoth

AU - Koganti, Praveen

AU - Shah, Pooja Anil

AU - Apel-Sarid, Liat

AU - Paolini, Biagio

AU - Detroja, Rajesh

AU - Frenkel-Morgenstern, Milana

AU - Blank, Michael

PY - 2019/4

Y1 - 2019/4

N2 - SMURF2, an E3 ubiquitin ligase and suggested tumor suppressor, operates in normal cells to prevent genomic instability and carcinogenesis. However, the mechanisms underlying SMURF2 inactivation in human malignancies remain elusive, as SMURF2 is rarely found mutated or deleted in cancers. We hypothesized that SMURF2 might have a distinct molecular biodistribution in cancer versus normal cells and tissues. The expression and localization of SMURF2 were analyzed in 666 human normal and cancer tissues, with primary focus on prostate and breast tumors. These investigations were accompanied by SMURF2 gene expression analyses, subcellular fractionation and biochemical studies, including SMURF2’s interactome analysis. We found that while in normal cells and tissues SMURF2 has a predominantly nuclear localization, in prostate and aggressive breast carcinomas SMURF2 shows a significantly increased cytoplasmic sequestration, associated with the disease progression. Mechanistic studies showed that the nuclear export machinery was not involved in cytoplasmic accumulation of SMURF2, while uncovered that its stability is markedly increased in the cytoplasmic compartment. Subsequent interactome analyses pointed to 14-3-3s as SMURF2 interactors, which could potentially affect its localization. These findings link the distorted expression of SMURF2 to human carcinogenesis and suggest the alterations in SMURF2 localization as a potential mechanism obliterating its tumor suppressor activities.

AB - SMURF2, an E3 ubiquitin ligase and suggested tumor suppressor, operates in normal cells to prevent genomic instability and carcinogenesis. However, the mechanisms underlying SMURF2 inactivation in human malignancies remain elusive, as SMURF2 is rarely found mutated or deleted in cancers. We hypothesized that SMURF2 might have a distinct molecular biodistribution in cancer versus normal cells and tissues. The expression and localization of SMURF2 were analyzed in 666 human normal and cancer tissues, with primary focus on prostate and breast tumors. These investigations were accompanied by SMURF2 gene expression analyses, subcellular fractionation and biochemical studies, including SMURF2’s interactome analysis. We found that while in normal cells and tissues SMURF2 has a predominantly nuclear localization, in prostate and aggressive breast carcinomas SMURF2 shows a significantly increased cytoplasmic sequestration, associated with the disease progression. Mechanistic studies showed that the nuclear export machinery was not involved in cytoplasmic accumulation of SMURF2, while uncovered that its stability is markedly increased in the cytoplasmic compartment. Subsequent interactome analyses pointed to 14-3-3s as SMURF2 interactors, which could potentially affect its localization. These findings link the distorted expression of SMURF2 to human carcinogenesis and suggest the alterations in SMURF2 localization as a potential mechanism obliterating its tumor suppressor activities.

KW - Gene and protein expression

KW - Interactome

KW - Molecular localization

KW - Prostate and breast cancer

KW - SMURF2

UR - http://www.scopus.com/inward/record.url?scp=85065412666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065412666&partnerID=8YFLogxK

U2 - 10.3390/cancers11040556

DO - 10.3390/cancers11040556

M3 - Article

AN - SCOPUS:85065412666

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 4

M1 - 556

ER -